Last reviewed · How we verify
Long-acting somatostatin
Long-acting somatostatin is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
Long-acting somatostatin is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Acromegaly, Neuroendocrine tumors, Carcinoid syndrome.
At a glance
| Generic name | Long-acting somatostatin |
|---|---|
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Somatostatin is a naturally occurring inhibitory peptide hormone that suppresses the release of growth hormone, insulin, glucagon, and other hormones. Long-acting formulations extend the duration of action, allowing for less frequent dosing. These analogs bind to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumor cells, providing sustained inhibition of hormone secretion and potential anti-proliferative effects.
Approved indications
- Acromegaly
- Neuroendocrine tumors
- Carcinoid syndrome
Common side effects
- Hyperglycemia / glucose intolerance
- Gallstone formation (cholelithiasis)
- Abdominal pain / gastrointestinal disturbance
- Injection site reactions
- Fatigue
Key clinical trials
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PHASE3)
- Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment (PHASE2)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (PHASE2)
- A Phase 1 Study of TE-8214 Solution in Healthy Volunteers (PHASE1)
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (PHASE4)
- Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long-acting somatostatin CI brief — competitive landscape report
- Long-acting somatostatin updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI